NKTR GoodMoat Verdict
Full signal breakdown coming soon. Use the X-Ray tool for a detailed analysis.
Nektar Therapeutics
Exchange: NASDAQSector: HealthcareIndustry: Biotechnology
Nektar Therapeutics is a clinical-stage biotechnology company focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. Nektar's lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel, first-in-class regulatory T cell stimulator being evaluated in one Phase 2b clinical trial in atopic dermatitis, one Phase 2b clinical trial in alopecia areata, and in one Phase 2 clinical trial in Type 1 diabetes mellitus. Nektar's pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. Nektar is headquartered in San Francisco, California.
Current Price
$70.62
-4.99%Profile
Valuation (TTM)
Market Cap$2.03B
P/E-12.81
EV—
P/B22.55
Shares Out28.69M
P/Sales36.42
Revenue$55.63M
EV/EBITDA—
Nektar Therapeutics (NKTR) Quality Analysis
NKTR Profitability
Profitability trend analysis coming soon
NKTR Growth
Growth trend analysis coming soon
NKTR Financial Health
Financial health indicators coming soon
NKTR Quality & Fundamental Analysis
Nektar Therapeutics (NKTR) is a Healthcare company in the Biotechnology industry, listed on NASDAQ. This quality analysis page evaluates Nektar Therapeutics's financial health using the Piotroski F-Score methodology, profitability ratios, growth trajectory, and balance sheet strength.
Nektar Therapeutics has a Piotroski F-Score of N/A out of 9, measuring profitability, leverage, and operating efficiency. The company operates with a profit margin of -284.18% and a return on equity (ROE) of -175.99%. Return on assets (ROA) stands at -56.38%.
The debt-to-equity ratio is 0.95, with a current ratio of 4.97. Operating margin is -253.66%.
GoodMoat's quality analysis uses AI-powered insights to evaluate whether Nektar Therapeutics is a fundamentally sound investment. The GoodMoat Verdict synthesizes profitability, growth, and financial health scores into a clear investment quality rating. Use these metrics alongside valuation tools like the DCF calculator and fair value models to make informed investment decisions.